Key result
CCTA demonstrates expanding utility across CAD stages for plaque quantification and risk assessment.
Why the study?
Evidence increasingly supports the clinical utility of CCTA across various stages of CAD, but an updated review of its clinical applications and emerging technologies is needed.
CCTA is increasingly recognized for its utility in CAD evaluation, plaque quantification, and emerging personalized risk assessment technologies.
Evaluation of coronary artery disease (CAD) using coronary computed tomography angiography (CCTA) has seen a paradigm shift in the last decade. Evidence increasingly supports the clinical utility of CCTA across various stages of CAD, from the detection of early subclinical disease to the assessment of acute chest pain. Additionally, CCTA can be used to noninvasively quantify plaque burden and identify high-risk plaque, aiding in diagnosis, prognosis, and treatment. This is especially important in the evaluation of CAD in immune-driven conditions with increased cardiovascular disease prevalence. Emerging applications of CCTA based on hemodynamic indices and plaque characterization may provide personalized risk assessment, affect disease detection, and further guide therapy. This review provides an update on the evidence, clinical applications, and emerging technologies surrounding CCTA as highlighted at the 2019 National Heart, Lung and Blood Institute CCTA Summit.
No takes yet. Share an insight, caveat, or question.
Abdelrahman et al. (2020) conducted a review in Coronary artery disease. Coronary computed tomography angiography (CCTA) was evaluated. Coronary computed tomography angiography (CCTA) has increasing evidence supporting its clinical utility across various stages of coronary artery disease, including plaque quantification and risk assessment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: